The independent, National Institutes of Health (NIH)-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, has informed Moderna Inc. that the trial for its COVID-19 vaccine ...

Moderna on Tuesday released preliminary data indicating its vaccine is likely to hold up against several variants of concern, including the Delta variant, which is predicted to become the dominant ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

CHICAGO, Sept 17 (Reuters) - If Moderna Inc's (MRNA.O), opens new tab COVID-19 vaccine proves to be at least 70% effective, the company plans to seek emergency authorization for its use in high-risk ...

Piper Sandler 37th Annual Healthcare Conference December 2, 2025 11:00 AM ESTCompany ParticipantsJames Mock - Chief ...

CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. “In the last three months, ...

Nov 11 (Reuters) - Moderna Inc (MRNA.O), opens new tab said on Wednesday it has enough data for a first interim analysis of the late-stage trial of its experimental COVID-19 vaccine, which should help ...

Moderna MRNA announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc GSK in a phase III ...